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Introduction
Anti-neutrophil cytoplasmic autoantibody (ANCA)-
associated vasculitides (AAV) constitutes a group of 
disorders characterized by autoimmune necrotizing in-
ﬂ   ammation of small blood vessels, which leads to 
systemic organ damage [1]. Th  is group of systemic 
vasculitides includes Wegener’s granulomatosis (WG), 
microscopic polyangiitis (MPA), and Churg–Strauss 
syndrome (CSS). Th  ese disorders are predominantly 
associated with the presence of circulating ANCAs that 
are directed against proteins in the cytoplasmic granules 
of neutrophils. ANCAs with speciﬁ  city for proteinase-3 
(PR3-ANCA) are associated with WG to a high degree, 
whereas ANCAs with speciﬁ   city for myeloperoxidase 
(MPO-ANCA) are predominant in MPA and to a lesser 
degree in CSS [2]. Although it remains unknown how 
these conditions develop, it has been postulated that 
ANCA  in vivo bind to surface-expressed autoantigens 
(PR3 or MPO) on primed neutrophils, which enhances 
neutrophil degranulation and the release of toxic products 
that cause endothelial damage, ultimately leading to 
necrotizing vasculitis [2].
In vivo experimental studies have clearly demonstrated 
that MPO-ANCAs are pathogenic factors. Xiao and 
colleagues have shown that immunization of MPO-
deﬁ   cient mice with mouse MPO results in an MPO-
directed immune response, and transfer of splenocytes 
from these mice into immune-deﬁ   cient mice leads to 
development of pauci-immune necrotizing crescentic 
glomerulonephritis and systemic necrotizing vasculitis 
reminiscent of MPA [3]. Further support for the patho-
genicity of ANCA comes from a recent study by van 
Timmeren and coworkers [4]. Th  ey observed that ad-
minis  tration of anti-MPO antibodies hydrolyzed by the 
bacterial enzyme endoglycosidase S, which abolishes IgG 
binding to Fcγ receptors, attenuated both neutrophil 
inﬂ  ux and formation of glomerular crescents in the above-
described model of MPO-ANCA-induced glomerulo-
nephritis. An immunopathogenic role for MPO-ANCA 
has also been strongly suggested by the occurrence of 
neonatal MPA in a child born to a mother with a history of 
MPO-ANCA-associated pulmonary renal syndrome [5].
In contrast to MPO-ANCA, in vivo evidence is still 
lacking for a direct vasculitic pathogenicity of PR3-
ANCA. So far only PR3-induced and PR3-ANCA-induced 
enhancement of inﬂ  ammation has been demonstrated in 
an animal model [6,7]. Recent ﬁ   ndings by Primo and 
colleagues suggest that, under certain conditions, anti-
PR3 antibodies can be pathogenic in rodents [8]. Th  ey 
showed that adoptive transfer of splenocytes from PR3-
immunized mice into NOD-SCID mice resulted in the 
appearance of circulating anti-PR3 antibodies and cres-
centic glomerulo  nephritis in the recipient mice. However, 
it is unclear whether glomerulonephritis in recipient 
mice is mediated by the humoral or the cellular arm of 
the anti-PR3 response.
Of note, inﬁ  ltrating T cells in granulomatous lesions as 
well as persistent T-cell activation have been reported in 
AAV patients [9-12]. Interestingly, T-cell-depleting therapy 
with anti-CD52 antibodies (alemtuzumab) and 
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© 2011 BioMed Central Ltdanti-thymocyte globulin can induce remission in 
refractory AAV patients [13,14]. Moreover, the IgG 
subclass distribution of ANCA, predominantly consisting 
of IgG1 and IgG4, implies isotype switching of ANCA for 
which CD4 T-helper cells are required [15]. T-cell-
mediated immunity is thus thought to contribute to the 
patho  genesis of ANCA-associated vasculitis. In the 
present review we will summarize the currently available 
data on the role of T cells in AAV. We shall ﬁ  rst discuss 
current thoughts about the contribution of T cells to 
tissue injury in AAV. Th   e main emphasis will then be on 
the plasticity of regulatory T cells (TRegs), their transition 
into Th  17 cells, and the involvement of Th  17 cells in 
granuloma formation and disease progression.
Involvement of CD4 T cells in AAV
Unlike other autoantibody-mediated diseases, AAV is 
characterized by an absence of deposited antibodies in 
aﬀ  ected tissue, in particular in glomeruli, designated as 
pauci-immune glomerular lesions [16]. Otherwise, 
immune eﬀ  ector cells such as CD4+ T cells, macrophages 
and granulocytes are enriched in granulomatous lesions 
[9,10,17-20]. Th   is suggests a primary role of cell-mediated 
immunity in initiating granuloma formation. Studies in 
mice and humans have demonstrated a key role of CD4+ 
T cells in the generation of a granulomatous response. 
For instance, Saunders and colleagues have shown that 
CD4-deﬁ  cient mice did not generate the typical mono-
nuclear granulomatous lesions following Mycobacterium 
tuberculosis infection [21]. In humans, the extent of 
granuloma formation was correlated with peripheral 
CD4 T-cell counts in HIV patients with mycobacterial 
infection [22,23]. Th  e important role of CD4 T cells in 
the expression of crescentic glomerulo  nephritis has been 
demonstrated by Ruth and colleagues [24]. Th  ey  induced 
experimental anti-MPO-associated crescentic glomerulo-
nephritis by immunizing C57BL/6 mice with human 
MPO followed by subsequent challenge with anti-
glomerular basement membrane antibodies. Mice 
depleted of CD4+ T cells at the time of adminis  tration of 
anti-mouse glomerular basement membrane developed 
signiﬁ  cantly less glomerular crescent forma  tion and less 
cell inﬂ  ux when compared with control mice. Th  ese  data 
provide convincing evidence that CD4+ T cells are crucial 
in granuloma formation and glomerulo  nephritis.
Studies in AAV patients also support this notion. 
Proliferation of CD4+ T cells in response to the auto-
antigens PR3 and MPO have been reported in patients 
with AAV, although CD4+ T cells from healthy controls 
also proliferated in response to PR3 and MPO, albeit to a 
lesser extent [25]. Persistent CD4 T-cell activation has 
also been observed in peripheral blood from AAV 
patients [26-28]. Importantly, Marinaki and colleagues 
observed an association between persistent CD4+ T-cell 
activation and disease severity in both WG patients and 
MPA patients [29]. Recently, Seta and colleagues 
evaluated the eﬀ  ect of depleting CD4 or CD8 T cells on 
the proliferative response to MPO fragments of peri-
pheral blood mononuclear cells isolated from MPA 
patients [30]. Strikingly, proliferation was completely lost 
after the depletion of CD4+ T cells, but not after depletion 
of CD8+ T cells. In our studies in WG patients, we 
observed a persistent expansion of a subset of memory 
CD4+ T cells, termed eﬀ  ector memory T cells (TEM), with 
a reciprocal decrease in naïve CD4+ T cells [11]. More-
over, the CD8+ T-cell compartment also appears to be 
altered [31,32]. In accordance, inﬁ  ltrating T cells in lung 
lesions and glomeruli were shown to consist mainly of 
CD4+ T cells with a memory phenotype [9,33,34]. Also in 
CSS patients, given the allergic background and hyper-
eosinophilia in this disease, activated CD4+ T cells 
producing Th  2 cytokines are believed to be the disease 
inducer [35]. Taken together, these ﬁ  ndings indicate that 
CD4 T cells can serve as eﬀ  ector cells in the pathogenesis 
of AAV.
CD4+ eff  ector memory T cells: a key player in tissue 
injury in AAV
As mentioned above, several observations support the 
involvement of CD4+ T cells in the pathogenesis of AAV. 
Important evidence regarding their role in disease mani-
festations came also from the clinical observation that 
remission could be induced in WG patients by antibodies 
directed at T cells [36]. Indeed, an altered phenotype of 
CD4+ T cells has been found in AAV patients. An 
increased proportion of CD45RCLowCD4+ memory T cells 
was reported in peripheral blood of AAV patients [37]. In 
addition, an expanded population of CD4+ T cells lacking 
the co-stimulatory molecule CD28 was observed in 
peripheral blood and in granulomatous lesions of patients 
with WG [9,38]. Th  ese CD28–CD4+ T cells display up-
regulation of the T-cell diﬀ  erentiation marker CD57 and 
show intracytoplasmic perforin expression, indicating the 
cytotoxic potential of these cells [9]. Based on phenotype 
and functional characteristics, CD28– T cells have been 
classiﬁ  ed as a TEM population that lacks the chemokine 
receptor CCR7 [39].
Consistent with these ﬁ   ndings, we observed a 
signiﬁ  cant increase in the frequency of circulating CD4+ 
TEM (CD45RO+CCR7–) in WG patients in remission com-
pared with healthy individuals [11]. In addition, we have 
shown that the number of these circulating CD4+ T EM 
decreases during active disease compared with that 
during complete remission, which is consistent with their 
migration towards inﬂ   amed tissues [11]. Indeed, our 
cross-sectional and follow-up studies conﬁ  rmed 
migration of CD4+ T EM during active renal disease into 
the diseased organs [40]. We observed a remarkable 
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concomitant decrease of circulating CD4+ T EM of WG 
patients with active renal involvement [40]. Th  ese  urinary 
CD4+ T EM decreased or disappeared from the urine 
during remission, which might reﬂ  ect their role in renal 
injury. In accordance with these ﬁ   ndings, Wilde and 
colleagues demonstrated that CD4+ T EM expressing 
CD134 are expanded in peripheral blood of patients with 
WG [41]. CD134 is thought to contribute to T-cell migra-
tion and tissue inﬁ  ltration through its interaction with 
OX40L on vascular endothelial cells [42]. Indeed, Wilde 
and coworkers have shown that CD134-expressing T cells 
were localized within the inﬂ  ammatory lesions of WG 
patients, supporting our hypothesis on migration of this 
T-cell subset to inﬂ  amed sites [41].
As mentioned, CD4+ T EM display natural killer (NK)-
like features such as cytotoxicity [39]. Th  ey also mimic 
NK cells by their surface expression of the NKG2D mole-
cule. NKG2D is an activating C-type lectin-like homo-
dimeric receptor, which diﬀ  ers from other NKG2 members 
as it apparently lacks an antagonist and substitutes for 
CD28-mediated co-stimulatory signaling in CD28– T EM 
[43]. One of the NKG2D ligands is the major histo  com-
patibility complex class-I chain-related molecule A 
(MICA), which is expressed upon cellular injury and 
stress on target cells such as ﬁ  broblasts and epithelial 
cells [43]. Proof of concept for NKG2D-mediated tissue 
destruction was provided by Allez and colleagues [44], 
who demonstrated that NKG2D+CD4+ T-cell clones from 
patients with Crohn’s disease kill target cells that express 
MICA via NKG2D–MICA interaction. Importantly, 
MICA is upregulated in peritubular endothelium and 
glomerular epithelial cells in AAV patients during active 
renal disease [45]. Strikingly, Capraru and colleagues 
have shown that NKG2D is preferentially expressed on 
expanded CD28–CD4+ T cells in the peripheral blood of 
WG patients [31]. Next, they showed that both NKG2D 
and MICA are expressed in granulomatous lesions in 
WG, but not in disease controls. Killing mechanisms via 
NKG2D–MICA interaction therefore probably contri-
bute to vessel injury and disease progression in AAV 
patients (Figure 1). Accordingly, selective targeting of 
NKG2D+CD4+ TEM or inhibiting MICA expression with-
out impairing other parts of cellular immunity might 
have value in the treatment of AAV [46].
Th1/Th2/Th17 paradigm in AAV
Aberrant T-helper cell polarization has been described in 
AAV. Analysis of soluble markers for T-helper cell subsets 
in patient sera reveals a predominance of the Th  1  pattern 
with expression of IFNγ and sCD26 in patients with 
localized WG and in patients with MPA, whereas a shift 
towards a Th  2 pattern, with expression of IL-4, IL-5, 
IL-10, IL-13, sCD23, and sCD30, was observed in active 
generalized WG and CSS [47,48]. Th   e same results were 
obtained from analysis of nasal granulomatous lesions in 
which abundant Th  1-associated markers (IFNγ, sCD26, 
CCR5) were seen during localized WG, whereas Th  1-
associated and Th   2-associated markers (IL-4 and CCR3) 
are found in generalized WG [20,49]. Besides the balance 
between Th  1 and Th  2, a recent breakthrough has 
revealed that IL-17-secreting T cells (Th   17) are another 
major pathogenic eﬀ   ector subset involved in the 
induction of inﬂ  ammation and autoimmunity [50,51]. It 
has been reported that induction of experimental auto-
immune encephalomyelitis (EAE) was blocked in mice 
deﬁ  cient in either IL-17 or the Th   17 polarizing cytokine 
IL-23, whereas mice deﬁ  cient in either IFNγ or the Th  1 
polarizing cytokine IL-12 show increased susceptibility 
to EAE [50,52,53]. Interestingly, Th  17 cells in EAE 
inﬁ  ltrate the brain prior to the onset of clinical symp-
toms, whereas Th  1 cells dominate the cellular inﬁ  ltrate 
thereafter when clinical disease develops [54]. It seems 
that T-cell-mediated disease manifestations are linked to 
Th   17 cells and not primarily to Th  1  responses.
Th  e physiological role of Th  17 cells lies in bacterial 
defense – for example, against Staphylococcus aureus – 
as shown in experimental pneumonia and the hyper-IgE 
syndrome [55,56]. Peptidoglycans as well as super-
antigens from S. aureus might have an immunomodu-
latory eﬀ  ect on dendritic cells by imprinting of a strong 
Th  17 polarizing capacity [57]. In addition, S. aureus 
α-toxin was shown to induce IL-17A secretion in CD4 
T cells [58]. Intriguingly, nasal S. aureus co-localization 
has been reported to be related to relapse and correlates 
with endonasal activity in WG [59,60]. Infection with 
S. aureus might therefore drive a Th   17 response in AAV 
patients. Indeed, in patients with AAV we observed a 
skewing towards Th   17 cells following in vitro stimulation 
of peripheral blood samples [61]. In line with this 
observation, Ordonez and coworkers have shown that 
the expanded CD4+ memory T cells in AAV patients are a 
source of IL-17 [37]. Most importantly, we found a 
relative increase in autoantigen-speciﬁ  c  Th  17 cells in 
ANCA-positive patients in com  parison with ANCA-
negative patients and controls [61]. Th  is observation 
suggests involvement of Th  17 cells in the process of 
autoantibody production in AAV. Th  ese results were 
corroborated by Nogueira and colleagues, who reported 
elevated levels of serum IL-17A and increased auto-
antigen-speciﬁ  c  Th  17 cells in AAV patients during 
disease convalescence compared with healthy controls 
[62]. In addition, Saito and colleagues observed an 
increased frequency of circulating Th   17 cells in patients 
with active CSS compared with in patients with inactive 
disease and healthy controls [63].
IL-17 has been reported to promote the release of pro-
inﬂ  ammatory cytokines, which are essential for triggering 
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neutrophils (priming of neutrophils), and also to induce 
CXC chemokine release and expression of adhesion 
molecules responsible for the recruitment of neutrophils 
to the site of inﬂ  ammation [64-66]. Indeed, WG granulo-
mata (site of inﬂ  ammation) are rich in neutrophils [20]. 
On the other hand, IL-17 has been shown crucial for the 
formation of an autoreactive germinal center in 
autoimmune BXD2 mice [67]. IL-17-producing T cells 
and B cells expressing the IL-17 receptor have also been 
reported to localize together in germinal centers [67]. 
Th  is observation suggests that IL-17 not only induces 
tissue inﬂ  ammation but also could function on B cells to 
promote the germinal center reaction. Th  e lymphocyte 
clusters in granuloma struc  tures can resemble germinal 
center-like structures that might be induced by IL-17 and 
may provide a place for ANCA production. IL-17 thus 
seems to be an important player in disease development 
in AAV and in early granuloma formation in WG, 
whereas Th  1 and Th  2 cells might prevail in later stages 
[20,49]. Of note, Th   17 cells have not so far been demon-
strated at inﬂ  amed sites in AAV.
Disturbance in the frequency and/or function of 
regulatory T cells in AAV
Natural TRegs, a subset of thymus-derived CD4+ T cells 
expressing a high level of IL-2Rα (CD25) and a unique 
transcription factor FoxP3, have been shown critical for 
preventing autoimmune responses. Defects in TReg func-
tion or reduced numbers of TRegs have been documented 
in several autoimmune diseases [68]. Indeed, we found 
that the suppressive function of TRegs was defective in 
WG patients as compared with healthy controls [69]. In 
this group of patients, however, we observed a signiﬁ  cant 
increase of memory FoxP3+CD25High T Regs. In line with 
these ﬁ   ndings, Klapa and colleagues  demonstrated an 
increased number of FoxP3+ T cells as well as pheno-
typical and functional alterations of TRegs in WG patients 
[70]. Th  ey reported an increased number of interferon 
receptor I-positive TRegs in the peripheral blood of WG 
patients [70]. In addition, they showed that IFNα 
exaggerates functional TReg impair  ment ex vivo in res-
ponse to the autoantigen PR3 [70]. TRegs in WG patients 
might thus display functional anergy in the context of an 
inﬂ  ammatory cytokine milieu.
Altered TReg function in WG patients has also been 
reported by Morgan and coworkers [71]. Th  ey  observed 
that TRegs from healthy controls and from ANCA-negative 
patients were able to suppress T-cell proliferation to PR3, 
whereas TRegs from ANCA-positive patients failed to 
suppress this autoimmune response [71]. Dysfunction of 
TRegs is thus believed to play a role in the development of 
WG. In contrast, TReg function in MPA patients was 
comparable with that in healthy controls, but FoxP3 
levels were diminished in MPA patients [72]. MPA seems 
to be associated with a numerical deﬁ  ciency rather than a 
functional deﬁ  ciency of TRegs. More  over, studies in CSS 
patients showed that both patients and controls have a 
similar number of CD25+CD4+ T cells with an equal 
percentage of FoxP3-expressing cells. However, the 
suppressive function of TRegs in CSS patients still needs to 
be investigated [63,73].
Plasticity of TRegs in AAV: conversion towards Th17 
eff  ector cells within an infl  ammatory milieu
A reciprocal relationship in the development of TRegs and 
Th   17 cells has recently been described. Th   is may underlie 
the propensity of TRegs to convert to Th  17 cells in the 
context of proinﬂ  ammatory stimuli, a phenomenon that 
has only recently been recognized [74-76]. Under neutral 
conditions in vitro, transforming growth factor beta can 
shift the balance towards functional FoxP3+ T Regs – 
whereas in the context of an inﬂ  ammatory  cytokine 
milieu (IL-1β, IL-2, IL-6, IL-15, IL-21, IL-23), functional 
TRegs convert towards IL-17-producing, nonfunctional 
TRegs. Th  e rela  tively novel notion of T-cell lineage plas-
ticity is of interest in relation to many papers describing 
nonfunctional TRegs in several autoimmune conditions, 
including AAV. Our hypothesis is that these nonfunc-
tional FoxP3+ T cells have lost their suppressive function 
due to co-expression of a second Th  17  lineage-associated 
transcription factor RORγt that interferes with Foxp3 
activity [77]. Recently, diﬀ  erent isoforms of FoxP3 have 
been investigated in human TRegs that have been shown to 
impact TReg function and lineage commitment. More 
speciﬁ  cally, the full-length isoform (FoxP3ﬂ  ) – but not 
the isoform lacking exon 2 (FoxP3Δ2) – interacts with 
RoRγt and inhibits the expression of genes that deﬁ  ne 
Th  17 cells [78-80]. Based on the aforementioned data, 
the putative nonfunctional TRegs described in AAV may 
lack their suppressive function due to upregulation of the 
FoxP3Δ2 isoform that fails to inhibit RORγt-mediated 
IL-17A mRNA trans  cription. Upon stimulation in an 
inﬂ   amed context, these cells convert into IL-17-
producing eﬀ  ector T cells.
Evidence from several groups of investigators, includ-
ing our own, support this hypothesis of conversion of 
TRegs into eﬀ  ector IL-17-secreting cells in AAV. As men-
tioned before, we found a signiﬁ   cant increase in the 
percentage of FoxP3+CD25High T Regs with a defective 
regulatory function in AAV patients in remission as 
compared with healthy controls. Furthermore, we 
demon  strated a concurrent increase in the percentage of 
Th  17  cells  upon  in vitro stimulation of peripheral blood 
samples from AAV patients. Consistent with this, 
patients with AAV had signiﬁ  cantly higher serum levels 
of IL-17 compared with healthy controls [62]. Import-
antly, increased serum levels of IL-17 in AAV patients 
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Page 4 of 9Figure 1. Proposed pathophysiological mechanisms of anti-neutrophil cytoplasmic autoantibody-associated vasculitides. Infl  ammatory 
cytokines (IL-1β, IL-6, transforming growth factor beta (TGFβ)) released due to bacterial or viral infections can promote skewing of a subset of 
functional regulatory T cells (TRegs) towards IL-17-producing nonfunctional TRegs. These IL-17-producing cells play a key role in disease onset through 
their cytokine IL-17. This cytokine induces CXC chemokine release from the target tissue that will attract neutrophils to the site of infl  ammation. In 
addition, IL-17 stimulates the release of IL-1β and TNFα from macrophages, which causes upregulation of the expression of endothelial adhesion 
molecules and induces translocation of proteinase-3 (PR3) and myeloperoxidase (MPO) to the neutrophil membrane (priming). Released PR3 
and MPO can be processed and presented by antigen-presenting cells (APC) to T-helper cells. Since TRegs are converted into nonfunctional IL-17-
producing cells that fail to inhibit this autoimmune response, autoreactive T cells may undergo repeated stimulation by PR3-pulsed or MPO-pulsed 
APC, resulting in a pool of eff  ector memory T cells (TEM). In addition, PR3-stimulated T-helper cells act on B cells. The presence of IL-17 can enhance 
the production of anti-neutrophil cytoplasmic autoantibody (ANCA) by autoreactive B cells. Subsequently, ANCA binds to PR3 or MPO on primed 
neutrophils that adhere to endothelial cells, which enhances neutrophil activation resulting in degranulation and release of reactive oxygen species 
(ROS) and proteolytic enzymes that can damage vascular endothelial cells. Moreover, persistent activation of T-helper cells by PR3 or MPO, together 
with the breakdown of TReg-mediated self-tolerance mechanisms, will induce autoreactive CD4+ TEM expansion. Expanded CD4+ TEM upregulate their 
killer immunoglobulin-like receptor (NKG2D) and interact with their ligand (major histocompatibility complex class-I chain-related molecule A 
(MICA)) on vascular endothelial cells, which in turn enhances their cytotoxic function and kills target cells in a perforin-dependent and granzyme-
dependent way, ending up in vasculitis.
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cytokines that are involved in the conversion of TRegs into 
Th   17 cells; that is, IL-1β, IL-23 and IL-6 [62]. In addition, 
patients with active CSS showed an increased frequency 
of Th   17 cells with a decrease in the frequency of IL-10-
producing TRegs, whereas an inverse result was observed 
in CSS patients with inactive disease [63]. Th  e 
aforementioned data appear to support a link between 
the conversion of TRegs into Th   17 cells and disease activity 
in AAV (Figure 1).
Therapeutic targets in patients with AAV
Because Th  17 cells contribute to inﬂ  ammation  and 
granuloma formation, this T-cell subset could be a novel 
therapeutic target for AAV. Depletion of Th  17 cells by 
targeting speciﬁ   c surface proteins may be diﬃ   cult  as 
Th   17 cells share many surface markers with other T-cell 
subsets. A therapeutic approach targeting its cytokine 
(that is, IL-17) would therefore be more feasible. Indeed, 
neutralizing IL-17 by anti-IL-17 antibody or by soluble 
IL-17 receptors reduces inﬂ  ammation and bone erosion 
in various animal arthritis models [81]. Interestingly, 
humanized anti-IL-17 mAbs – including AIN457 and 
LY2439821, which neutralize the biologic activity of 
IL-17 – are in clinical trials. Th   ese biologicals have been 
shown to induce clinically relevant responses in patients 
with psoriasis, rheumatoid arthritis, and non-infectious 
uveitis, compared with placebo without safety issues 
[82,83]. Neutralization of IL-17 could therefore represent 
a novel therapeutic approach for patients with AAV.
On the other hand, CD4+ T EM – supposed to act as a 
key trigger of disease expression and relapse in AAV – 
may also serve as a therapeutic target. Selective targeting 
of CD4+ T EM without impairing other parts of the 
humoral and cellular immune system could be a major 
step forward in the treatment of AAV. NKG2D blockade 
by anti-NKG2D antibodies has been reported to prevent 
autoimmune diabetes in NOD mice [84]. Blocking of 
NKG2D could be a new strategy in the treatment of AAV. 
Other studies have revealed that targeting of the voltage-
gated Kv1.3 channel, which is highly expressed on 
activated CD4+ T EM, provides a speciﬁ  c immunomodu-
latory approach [85,86]. Blockade of the Kv1.3 channel by 
ShK(L5) amide eﬀ  ectively prevented autoimmune disease 
in the EAE model of multiple sclerosis and suppressed 
delayed-type hypersensitivity in rats [85,86]. Th  e  selective 
targeting of CD4+ T EM using ShK(L5) amide and/or 
blocking the NKG2D–MICA interaction by anti-NKG2D 
antibodies may therefore hold therapeutic promise for 
AAV.
Conclusion
CD4+ TEM seem to be involved in tissue damage and renal 
injury in patients with AAV. Besides CD4+ TEM, impaired 
TReg function and an increased Th  17 response are also 
reported in AAV patients. During the past 2 years, 
multiple studies indicate a link between TRegs and Th  17 
cells. Indeed, in the context of an inﬂ  ammatory cytokine 
milieu, conversion of TRegs into IL-17-producing cells has 
been demonstrated. Evidence from several studies 
supports this conversion in AAV patients. Defective TReg 
function in AAV patients can thus be explained by their 
conversion into eﬀ  ector Th   17 cells. Instead of suppressing 
autoreactive responses, these converted TRegs – through 
production of IL-17 – can participate in granuloma 
forma  tion and tissue injury, which contribute to necro-
tiz  ing granulomatous vasculitis in AAV patients. Th  e 
mechanisms underlying the conversion of suppressive 
TRegs into nonfunctional TRegs in AAV await further 
investigation. Th   is novel view into the role of converted 
TRegs in the pathophysiology of vasculitis will improve our 
understanding of AAV pathogenesis, which may lead to 
the identiﬁ   cation of new biomarkers and targets for 
therapeutic intervention.
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